Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2022; 14(9): 1804-1816
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1804
Hereditary hemochromatosis: Temporal trends, sociodemographic characteristics, and independent risk factor of hepatocellular cancer – nationwide population-based study
Maryam Bilal Haider, Ali Al Sbihi, Ahmed Jamal Chaudhary, Syed M Haider, Ahmed Iqbal Edhi
Maryam Bilal Haider, Ali Al Sbihi, Ahmed Jamal Chaudhary, Department of Internal Medicine, Detroit Medical Center, Wayne State University, Sinai Grace Hospital, Detroit, MI 48235, United States
Syed M Haider, System Science, Binghamton University, Binghamton, NY 13902, United States
Ahmed Iqbal Edhi, Department of Gastroenterology, William Beaumont Hospital, Royal Oak, MI 48073, United States
Author contributions: Haider M was responsible for study design and interpretations of results; Haider M and Al Sbihi A were responsible for literature review and manuscript preparation; Haider S was responsible for data collection; Chaudhary A and Edhi A were responsible for the overall supervision and final approval.
Institutional review board statement: Data from this study used de-identified data from the National Inpatient Sample Database (NIS) 2011-2019. A publicly available all-payer inpatient care database in the United States. Institutional Review Board Approval Form or Document is not required.
Informed consent statement: Data from this study used de-identified data from the National Inpatient Sample Database. A publicly available all-payer inpatient care database in the United States. Informed patient consent is not required.
Conflict-of-interest statement: All authors declare no conflict of interests for this article.
Data sharing statement: Data that support the findings of this study are publicly available at https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maryam Bilal Haider, MD, Doctor, Department of Internal Medicine, Detroit Medical Center, Wayne State University, Sinai Grace Hospital, 6071 Outer Dr W, Detroit, MI 48235, United States. maryambilalhaider@yahoo.com
Received: May 5, 2022
Peer-review started: May 5, 2022
First decision: June 8, 2022
Revised: June 20, 2022
Accepted: August 25, 2022
Article in press: August 25, 2022
Published online: September 27, 2022
Processing time: 140 Days and 11.9 Hours
Abstract
BACKGROUND

Hereditary hemochromatosis (HH) has an increased risk of hepatocellular cancer (HCC) both due to genetic risks and iron overload as iron overload can be carcinogenic; HH impacts the increasing risk of HCC, not only through the development of cirrhosis but concerning hepatic iron deposition, which has been studied further recently.

AIM

To evaluate HH yearly trends, patient demographics, symptoms, comorbidities, and hospital outcomes. The secondary aim sheds light on the risk of iron overload for developing HCC in HH patients, independent of liver cirrhosis complications. The study investigated HH (without cirrhosis) as an independent risk factor for HCC.

METHODS

We analyzed data from National Inpatient Sample (NIS) Database, the largest national inpatient data collection in the United States, and selected HH and HCC cohorts. HH was first defined in 2011 International Classification of Disease - 9th edition (ICD-9) as a separate diagnosis; the HH cohort is extracted from January 2011 to December 2019 using 275.01 (ICD-9) and E83.110 (ICD-10) diagnosis codes of HH. Patients were excluded from the HH cohort if they had a primary or secondary diagnostic code of cirrhosis (alcoholic, non-alcoholic, and biliary), viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). We removed these patients from the HH cohort to rule out bias or ICD-10 diagnostic errors. The HCC cohort is selected from January 2011 to December 2019 using the ICD-9 and ICD-10 codes of HCC. We selected a non-HCC cohort with the 1:1 fixed ratio nearest neighbor (greedy) propensity score method using the patients' age, gender, and race. We performed multivariate analysis for the risk factors of HCC in the HCC and non-HCC matched cohort. We further analyzed HH without cirrhosis (removing HH patients with a diagnosis of cirrhosis) as an independent risk factor of HCC after adjusting all known risk factors of HCC in the multivariate model.

RESULTS

During the 2011-2019 period, a total of 18031 hospitalizations with a primary or secondary diagnosis of HH (excluding liver diseases) were recorded in the NIS database. We analyzed different patients’ characteristics, and we found increments in inpatient population trend with a Ptrend < 0.001 and total hospital cost of care trend from $42957 in 2011 to $66152 in 2019 with a Ptrend < 0.001 despite no change in Length of Stay over the last decade. The multivariate analyses showed that HH without cirrhosis (aOR, 28.8; 95%CI, 10.4–80.1; P < 0.0001), biliary cirrhosis (aOR, 19.3; 95%CI, 13.4–27.6; P < 0.0001), non-alcoholic cirrhosis (aOR, 17.4; 95%CI, 16.5–18.4; P < 0.0001), alcoholic cirrhosis (aOR, 16.9; 95%CI, 15.9–17.9; P < 0.0001), hepatitis B (aOR, 12.1; 95%CI, 10.85–13.60; P < 0.0001), hepatitis C (aOR, 8.58; 95%CI, 8.20–8.98; P < 0.0001), Wilson disease (aOR, 4.27; 95%CI, 1.18–15.41; P < 0.0001), NAFLD or NASH (aOR, 2.96; 95%CI, 2.73–3.20; P < 0.0001), alpha1-antitrypsin deficiency (aOR, 2.10; 95%CI, 1.21–3.64; P < 0.0001), diabetes mellitus without chronic complications (aOR, 1.17; 95%CI, 1.13–1.21; P < 0.0001), and blood transfusion (aOR, 1.80; 95%CI, 1.69–1.92; P < 0.0001) are independent risk factor for liver cancer.

CONCLUSION

Our study showed an increasing trend of in-hospital admissions of HH patients in the last decade. These trends were likely related to advances in diagnostic approach, which can lead to increased hospital utilization and cost increments. Still, the length of stay remained the same, likely due to a big part of management being done in outpatient settings. Another vital part of our study is the significant result that HH without cirrhosis is an independent risk factor for HCC with adjusting all known risk factors. More prospective and retrospective large studies are needed to re-evaluate the HH independent risk in developing HCC.

Keywords: Hereditary hemochromatosis; Hepatocellular carcinoma, cirrhosis; Hepatitis; Diabetes mellitus; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Wilson disease; Alpha1-antitrypsin deficiency; Blood transfusion; Epidemiology; Demographics; Big data; Hospitalization

Core Tip: Our study is a National Inpatient Sample -based study in which we aim to analyze hereditary hemochromatosis (HH) patients’ characteristics, temporal trends, and sociodemographic characteristics over the last decade, in addition to studying this disease as an independent risk factor for developing hepatocellular cancer (HCC) without the stage of liver cirrhosis. Our large and diverse sample of about 18000 HH hospitalizations showed an increasing trend of inpatient admissions and costs with a similar length of hospital stay over the last decade. It also showed HH as an independent risk factor for HCC with an aOR close to 29 on multivariate analysis. We believe this will open the door for further retrospective and prospective studies to address disease trends and the understudied and independent relationship between HH and HCC in a large patient cohort.